Bank of New York Mellon Corp boosted its position in Sanofi (NASDAQ:SNY) by 4.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 288,117 shares of the company’s stock after buying an additional 13,519 shares during the quarter. Bank of New York Mellon Corp’s holdings in Sanofi were worth $15,173,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC purchased a new position in shares of Sanofi in the second quarter valued at $25,000. First Eagle Investment Management LLC grew its position in shares of Sanofi by 99.2% in the first quarter. First Eagle Investment Management LLC now owns 733 shares of the company’s stock valued at $36,000 after purchasing an additional 365 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. purchased a new position in shares of Sanofi in the first quarter valued at $38,000. Meridian Wealth Partners LLC boosted its stake in Sanofi by 46.6% during the first quarter. Meridian Wealth Partners LLC now owns 777 shares of the company’s stock valued at $39,000 after buying an additional 247 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA boosted its stake in Sanofi by 1,400.0% during the first quarter. Kelly Lawrence W & Associates Inc. CA now owns 1,125 shares of the company’s stock valued at $56,000 after buying an additional 1,050 shares during the period. 8.02% of the stock is owned by institutional investors and hedge funds.
In related news, major shareholder Sanofi bought 66,667 shares of the stock in a transaction dated Monday, August 2nd. The stock was bought at an average price of $15.00 per share, with a total value of $1,000,005.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.00% of the company’s stock.
Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 29th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.04. Sanofi had a return on equity of 24.31% and a net margin of 16.02%. The firm had revenue of $10.53 billion during the quarter, compared to analyst estimates of $10.29 billion. As a group, research analysts expect that Sanofi will post 3.85 EPS for the current fiscal year.
SNY has been the subject of several research analyst reports. UBS Group reissued a “buy” rating on shares of Sanofi in a research note on Thursday, August 12th. SVB Leerink raised Sanofi from a “market perform” rating to an “outperform” rating in a research note on Monday, September 27th. Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a research note on Friday, August 6th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $51.00 price target for the company in a research note on Wednesday, September 29th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Sanofi in a research note on Friday, July 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $51.00.
Sanofi Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
Featured Story: Is it Safe to Invest in Commodities?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.